Will Intra-Osseous Injection of Umbilical Cord Blood Reduce Graft Failures?



Released on: July 10, 2010, 6:22 am
Author: Cryo-Cell International, Inc.
Industry: Biotech

Researchers from Italy have reported that the injection of umbilical cord blood directly into the pelvic bones of patients with leukemia appears promising. These results were recently published in an early online publication of the Lancet Oncology on August 9, 2008.

Transplantation of bone marrow, peripheral blood stem cells, and umbilical cord blood is accomplished by intravenous infusion. The original studies of human bone marrow transplantation were carried out by direct infusion into bone marrow spaces. However, this approach was abandoned as there was no advantage in speed or rate of engraftment over intravenous infusion. Since these early days of transplantation, there have been sporadic attempts to evaluate intra-osseous infusion of stem cells, but no advantage over intravenous infusion was ever found. The reason for this is thought to be that direct infusion of stem cells into the marrow cavity is in fact identical to intra-arterial or intra-venous infusion, and most stem cells enter the general circulation before homing into marrow spaces throughout the body.

Umbilical cord blood transplantation is associated with relatively high graft failure rates thought to be due to the relatively low dose of stem cells in each collection. Researchers have suggested that the infusion of stem cells from two separate cord blood collections alleviates the graft failure problem. However, Italian researches have posed the question of whether or not intra-osseous infusion would be better.

The current trial evaluated direct infusion of umbilical cord blood into the pelvic bones. This trial included 32 patients with acute myeloid leukemia (AML) and 12 with acute lymphoblastic leukemia (ALL); median age was 36 years. Overall, 14 patients had advanced-stage disease that did not respond to standard therapies, and no patient had a suitable donor for the stem cell transplant.

  • No complications occurred during the infusion of stem cells into the bone marrow.
  • 28 of the 32 patients recovered neutrophil function and 27 recovered platelet function.
  • The median time to recovery of 500 neutrophils was 28 days and the median time to recovery of platelets to 20,000 was 36 days.
  • No patient developed acute, severe GVHD.
  • At 13 months 16 patients were alive and in complete remission.
  • Five patients died from treatment-related complications of the transplant, seven died from infection, and four patients died from a relapse of their disease.

The researchers concluded that these results [lead] to the possibility of use of this technique in a large number of adult patients. Although this technique is still under investigation, it provides promise for the future of patients with leukemia.

About C'elle
The C'elleSM service was introduced in November 2007 as the first and only service that empowers women to collect and cryopreserve menstrual flow containing undifferentiated adult stem cells for future utilization by the donor or possibly their first-degree relatives in a manner similar to umbilical cord blood stem cells. For more information, visit www.celle.com.

About Cryo-Cell International, Inc. (OTCBB: CCEL.OB)
Based in Oldsmar, Florida, with nearly 200,000 clients worldwide, Cryo-Cell is a global leader in stem cell innovation. ISO 9001:2000 certified and accredited by the AABB, Cryo-Cell operates in a state-of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility. Cryo-Cell is a publicly traded company. OTC Bulletin Board Symbol: CCEL. For more information, please call 1-800-STOR-CELL (1-800-786-7235) or visit www.cryo-cell.com.



Back to previous page
Home page
Submit your press release